Artilysin – A Groundbreaking “Green Pharma” Solution
Embracing the "green pharma" philosophy, Lysando's Artilysin molecules effectively target resistant pathogens while minimizing environmental, wastewater, and food…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Jun 23
Embracing the "green pharma" philosophy, Lysando's Artilysin molecules effectively target resistant pathogens while minimizing environmental, wastewater, and food…
23 Jun 23
The merged firm will concentrate on developing Tourmaline's TOUR006 programme, an anti-IL-6 antibody to treat thyroid eye disease…
23 Jun 23
Lunaphore’s spatial biology portfolio uses precision microfluidic technology to find hyperplex proteomic and transcriptomic biomarkers in tumours and…
23 Jun 23
UPM Biomedicals’ innovative wound dressing FibDex is undergoing a clinical investigation of performance and safety in patients with…
23 Jun 23
The Sponsored Research Agreement will help advance antidepressant treatments for patients in need
22 Jun 23
AstraZeneca has discontinued and ceased dosing in the ongoing clinical studies of IL-4 receptor based on the lung…
22 Jun 23
The approval was based on the findings from the DINAMO Phase 3 trial of patients aged 10-17 years…
22 Jun 23
In two different votes, the advisory committee agreed that individuals of 60 years and more can get the…
21 Jun 23
The approval was backed by the statistically significant and clinically meaningful radiographic progression-free survival (rPFS) data from the…
21 Jun 23
The FDA approval was based on the findings from the Phase 3 ADAPT-SC study that validated the efficacy…